

Thomas J Giordano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7488077/publications.pdf>

Version: 2024-02-01

206
papers

27,528
citations

10389

72
h-index

5829

161
g-index

211
all docs

211
docs citations

211
times ranked

32567
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic mutations affect key pathways in lung adenocarcinoma. <i>Nature</i> , 2008, 455, 1069-1075.	27.8	2,694
2	Gene-expression profiles predict survival of patients with lung adenocarcinoma. <i>Nature Medicine</i> , 2002, 8, 816-824.	30.7	1,788
3	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1023.	7.1	1,192
4	p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes. <i>Current Biology</i> , 2007, 17, 1298-1307.	3.9	1,045
5	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007, 450, 893-898.	27.8	1,020
6	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827.	30.7	1,015
7	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009, 41, 1238-1242.	21.4	862
8	Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 304-313.	3.8	813
9	Adrenocortical Carcinoma. <i>Endocrine Reviews</i> , 2014, 35, 282-326.	20.1	671
10	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
11	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
12	Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas. <i>American Journal of Surgical Pathology</i> , 2006, 30, 216-222.	3.7	467
13	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010, 16, 793-798.	30.7	436
14	Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2. <i>Immunity</i> , 2013, 39, 611-621.	14.3	366
15	Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling. <i>Clinical Cancer Research</i> , 2009, 15, 668-676.	7.0	356
16	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. <i>Oncogene</i> , 2005, 24, 6646-6656.	5.9	354
17	Management of patients with adrenal cancer: recommendations of an international consensus conference. <i>Endocrine-Related Cancer</i> , 2005, 12, 667-680.	3.1	354
18	Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis. <i>American Journal of Pathology</i> , 2003, 162, 521-531.	3.8	338

#	ARTICLE	IF	CITATIONS
19	Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. <i>Cancer Cell</i> , 2005, 8, 13-23.	16.8	338
20	Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. <i>Cancer Research</i> , 2002, 62, 4722-9.	0.9	321
21	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. <i>Nature Medicine</i> , 2011, 17, 1646-1651.	30.7	301
22	Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , 2004, 11, 423-436.	3.1	299
23	NF- κ B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. <i>Nature Medicine</i> , 2007, 13, 62-69.	30.7	296
24	An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9824-9829.	7.1	286
25	Protein profiles associated with survival in lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13537-13542.	7.1	262
26	Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4591-9.	7.1	256
27	EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. <i>Neoplasia</i> , 2008, 10, 298-302.	5.3	231
28	Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. <i>Clinical Cancer Research</i> , 2002, 8, 2298-305.	7.0	230
29	Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 437-447.	3.7	216
30	Organ-Specific Molecular Classification of Primary Lung, Colon, and Ovarian Adenocarcinomas Using Gene Expression Profiles. <i>American Journal of Pathology</i> , 2001, 159, 1231-1238.	3.8	180
31	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. <i>Oncogene</i> , 2008, 27, 6623-6634.	5.9	178
32	Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 204-212.	3.6	177
33	Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2016, 174, 601-609.	3.7	168
34	B-Raf ^{V600E} and thrombospondin-1 promote thyroid cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10649-10654.	7.1	164
35	Progression of BRAF-induced thyroid cancer is associated with epithelial \rightarrow mesenchymal transition requiring concomitant MAP kinase and TGF β 2 signaling. <i>Oncogene</i> , 2011, 30, 3153-3162.	5.9	160
36	Progression to Adrenocortical Tumorigenesis in Mice and Humans through Insulin-Like Growth Factor 2 and β -Catenin. <i>American Journal of Pathology</i> , 2012, 181, 1017-1033.	3.8	154

#	ARTICLE	IF	CITATIONS
37	Adrenocortical Carcinoma Is a Lynch Syndrome-Associated Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3012-3018.	1.6	153
38	Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features. <i>JAMA Oncology</i> , 2018, 4, 1125.	7.1	151
39	Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast. <i>Clinical Cancer Research</i> , 2008, 14, 4038-4044.	7.0	144
40	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	136
41	Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma. <i>Cancer Research</i> , 2004, 64, 2047-2053.	0.9	135
42	International Histopathology Consensus for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 42-54.	3.6	127
43	Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation. <i>Clinical Cancer Research</i> , 2006, 12, 1983-1993.	7.0	125
44	Upregulated INHBA Expression May Promote Cell Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma. <i>Neoplasia</i> , 2009, 11, 388-396.	5.3	125
45	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. <i>Clinical Cancer Research</i> , 2005, 11, 565-72.	7.0	125
46	Phosphorylated FADD induces NF- κ B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 12507-12512.	7.1	122
47	Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3869-3876.	3.6	122
48	Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. <i>Hypertension</i> , 2019, 73, 885-892.	2.7	121
49	An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer. <i>Cancer Research</i> , 2004, 64, 5504-5510.	0.9	119
50	A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2010, 20, 975-980.	4.5	116
51	Pathologic, Immunohistochemical, and Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast. <i>Modern Pathology</i> , 2001, 14, 185-190.	5.5	113
52	Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. <i>Human Pathology</i> , 1998, 29, 131-136.	2.0	111
53	Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. <i>BMC Bioinformatics</i> , 2005, 6, 26.	2.6	109
54	Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. <i>Journal of Pathology</i> , 2004, 202, 321-329.	4.5	108

#	ARTICLE	IF	CITATIONS
55	Molecular Profiling and the Identification of Genes Associated With Metastatic Oral Cavity/Pharynx Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 2004, 130, 295.	1.2	106
56	Distinct Gene Expression Profiles of Viral- and Nonviral-Associated Merkel Cell Carcinoma Revealed by Transcriptome Analysis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 936-945.	0.7	98
57	<i>CYP24A1</i> is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 817-826.	7.0	96
58	Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2585-2592.	0.7	96
59	Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. <i>Modern Pathology</i> , 2020, 33, 1264-1274.	5.5	96
60	Differential immunohistochemical detection of transforming growth factor β , amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95
61	Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis. <i>Clinical Cancer Research</i> , 2004, 10, 6703-6709.	7.0	94
62	The Molecular Basis of Pancreatic Fibrosis. <i>Pancreas</i> , 2004, 29, 254-263.	1.1	90
63	Curcumin Promotes Apoptosis, Increases Chemosensitivity, and Inhibits Nuclear Factor κ B in Esophageal Adenocarcinoma. <i>Translational Oncology</i> , 2010, 3, 99-108.	3.7	89
64	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 1439-1444.	7.1	87
65	Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma. <i>Modern Pathology</i> , 2000, 13, 742-746.	5.5	86
66	Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2481-2485.	1.6	86
67	Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma. <i>Cancer Research</i> , 2007, 67, 3461-3467.	0.9	86
68	RANTES expression is a predictor of survival in stage I lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2002, 8, 3803-12.	7.0	83
69	Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. <i>Oncogene</i> , 2003, 22, 7950-7957.	5.9	81
70	Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. <i>Cancer</i> , 2005, 103, 830-838.	4.1	81
71	Role and regulation of coordinately expressed <i>de novo</i> purine biosynthetic enzymes <i>PPAT</i> and <i>PAICS</i> in lung cancer. <i>Oncotarget</i> , 2015, 6, 23445-23461.	1.8	80
72	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 2042-2050.	3.4	78

#	ARTICLE	IF	CITATIONS
73	Activation of GATA binding protein 6 (<i>GATA6</i>) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4251-4256.	7.1	76
74	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	3.7	75
75	Proteomic Analysis of Cytokeratin Isoforms Uncovers Association with Survival in Lung Adenocarcinoma. Neoplasia, 2002, 4, 440-448.	5.3	74
76	Notch signaling regulates gastric antral LGR 5 stem cell function. EMBO Journal, 2015, 34, 2522-2536.	7.8	74
77	Molecular Heterogeneity in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 999-1007.	3.6	74
78	Overexpression of Oncoprotein 18 Correlates with Poor Differentiation in Lung Adenocarcinomas. Molecular and Cellular Proteomics, 2003, 2, 107-116.	3.8	73
79	The Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule: Implications for Clinical Research. Annual Review of Medicine, 2006, 57, 575-590.	12.2	73
80	Multiplatform molecular test performance in indeterminate thyroid nodules. Diagnostic Cytopathology, 2020, 48, 1254-1264.	1.0	73
81	Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biology and Therapy, 2007, 6, 1143-1147.	3.4	70
82	HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocrine-Related Cancer, 2007, 14, 445-452.	3.1	70
83	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	17.5	69
84	Decreased Selenium-Binding Protein 1 in Esophageal Adenocarcinoma Results from Posttranscriptional and Epigenetic Regulation and Affects Chemosensitivity. Clinical Cancer Research, 2010, 16, 2009-2021.	7.0	69
85	Gene Expression Differences between Colon and Rectum Tumors. Clinical Cancer Research, 2011, 17, 7303-7312.	7.0	69
86	Somatic <i>CACNA1H</i> Mutation As a Cause of Aldosterone-Producing Adenoma. Hypertension, 2020, 75, 645-649.	2.7	69
87	Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clinical Cancer Research, 2002, 8, 788-93.	7.0	69
88	Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clinical Endocrinology, 2017, 87, 665-672.	2.4	68
89	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer, 2007, 109, 957-965.	4.1	66
90	Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbeck's Archives of Surgery, 2010, 395, 955-961.	1.9	65

#	ARTICLE	IF	CITATIONS
91	131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. , 1996, 78, 2184-2192.		64
92	Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based Framework. American Journal of Pathology, 2003, 163, 1985-1995.	3.8	64
93	Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes and Control, 2010, 21, 737-743.	1.8	60
94	L-Type Amino Acid Transporter-1 Overexpression and Melphalan Sensitivity in Barrett's Adenocarcinoma. Neoplasia, 2004, 6, 74-84.	5.3	59
95	Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer, 2012, 77, 265-271.	2.0	58
96	Regulation of coliphage T3 and T7 RNA polymerases by the lac repressor-operator system. Gene, 1989, 84, 209-219.	2.2	57
97	Analysis of Tumor-Host Interactions by Gene Expression Profiling of Lung Adenocarcinoma Xenografts Identifies Genes Involved in Tumor Formation. Molecular Cancer Research, 2005, 3, 119-129.	3.4	57
98	Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. Clinical Cancer Research, 2009, 15, 2829-2839.	7.0	57
99	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. European Urology, 2020, 78, 63-74.	1.9	57
100	Expression and Effect of Inhibition of the Ubiquitin-Conjugating Enzyme E2C on Esophageal Adenocarcinoma. Neoplasia, 2006, 8, 1062-1071.	5.3	56
101	Does <i>BRAF</i> V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3702-3712.	3.6	55
102	Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist?. Thyroid, 2015, 25, 1-2.	4.5	54
103	INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 455-462.	1.1	53
104	Pioglitazone Induces a Proadipogenic Antitumor Response in Mice with PAX8-PPAR β Fusion Protein Thyroid Carcinoma. Endocrinology, 2011, 152, 4455-4465.	2.8	52
105	Melanoma-Associated Antigens in Esophageal Adenocarcinoma. Clinical Cancer Research, 2004, 10, 5708-5716.	7.0	51
106	Targeted Assessment of <i>GOS2</i> Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clinical Cancer Research, 2019, 25, 3276-3288.	7.0	51
107	IRS1 Regulation by Wnt/ β -Catenin Signaling and Varied Contribution of IRS1 to the Neoplastic Phenotype. Journal of Biological Chemistry, 2010, 285, 1928-1938.	3.4	50
108	Association of <i>BRAF</i> ^{V600E} Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid, 2016, 26, 532-542.	4.5	50

#	ARTICLE	IF	CITATIONS
109	Genomic Hallmarks of Thyroid Neoplasia. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 141-162.	22.4	50
110	Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatric Blood and Cancer, 2006, 46, 614-623.	1.5	48
111	AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 1236-1244.	1.1	47
112	The Cancer Genome Atlas Research Network: A Sight to Behold. Endocrine Pathology, 2014, 25, 362-365.	9.0	47
113	Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. Human Pathology, 2014, 45, 1339-1347.	2.0	47
114	Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations. Journal of Pathology: Clinical Research, 2016, 2, 93-103.	3.0	47
115	Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery, 2019, 165, 186-195.	1.9	47
116	CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology, 2005, 128, 946-961.	1.3	45
117	Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1442-1449.	3.6	45
118	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocrine Pathology, 2018, 29, 137-149.	9.0	45
119	Expression Levels of Protein Kinase C- β in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 6, 184-189.	2.6	44
120	Interferon Regulatory Factor 1 (IRF-1) and IRF-2 Expression in Breast Cancer Tissue Microarrays. Journal of Interferon and Cytokine Research, 2005, 25, 587-594.	1.2	44
121	GSK3 β and β -Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer. Neoplasia, 2010, 12, 357-365.	5.3	43
122	Proteomic analysis of eIF-5A in lung adenocarcinomas. Proteomics, 2003, 3, 496-504.	2.2	41
123	Metastasis-associated <i>MCL1</i> and <i>P16</i> copy number alterations dictate resistance to vemurafenib in a <i>BRAFV600E</i> patient-derived papillary thyroid carcinoma preclinical model. Oncotarget, 2015, 6, 42445-42467.	1.8	40
124	Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3286-3294.	3.6	39
125	Stromal LRP1 in Lung Adenocarcinoma Predicts Clinical Outcome. Clinical Cancer Research, 2011, 17, 2426-2433.	7.0	39
126	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Human Pathology, 2018, 71, 47-54.	2.0	39

#	ARTICLE	IF	CITATIONS
127	Overexpression of CXC Chemokines by an Adrenocortical Carcinoma: A Novel Clinical Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3968-3974.	3.6	38
128	CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells. <i>Lung Cancer</i> , 2013, 82, 477-484.	2.0	37
129	Follicular cell thyroid neoplasia. <i>Current Opinion in Oncology</i> , 2016, 28, 1-4.	2.4	37
130	Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. <i>European Journal of Endocrinology</i> , 2016, 175, K1-K6.	3.7	37
131	EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. <i>Human Molecular Genetics</i> , 2016, 25, ddw136.	2.9	37
132	Pitfalls in the surgical treatment of insulinoma. <i>Surgery</i> , 2002, 132, 1040-1049.	1.9	35
133	Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. <i>Cell Death and Differentiation</i> , 2002, 9, 274-286.	11.2	35
134	Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3743-3750.	3.6	35
135	Odontogenic Keratocysts Arise from Quiescent Epithelial Rests and Are Associated with Deregulated Hedgehog Signaling in Mice and Humans. <i>American Journal of Pathology</i> , 2006, 169, 806-814.	3.8	34
136	Comparative Proteomics Analysis of Barrett Metaplasia and Esophageal Adenocarcinoma Using Two-dimensional Liquid Mass Mapping. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 987-999.	3.8	33
137	Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non-muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 3810-3818.	0.9	33
138	The Argument for Mitotic Rate-based Grading for the Prognostication of Adrenocortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 471-473.	3.7	33
139	Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2452-2464.	7.0	33
140	What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. <i>Endocrine Pathology</i> , 2021, 32, 102-133.	9.0	33
141	Optimization of the hygromycin B resistance-conferring gene as a dominant selectable marker in mammalian cells. <i>Gene</i> , 1990, 88, 285-288.	2.2	32
142	Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression. <i>Endocrine Pathology</i> , 2000, 11, 137-144.	9.0	32
143	Differential Protein Mapping of Ovarian Serous Adenocarcinomas: Identification of Potential Markers for Distinct Tumor Stage. <i>Journal of Proteome Research</i> , 2009, 8, 1452-1463.	3.7	32
144	Gene expression profiling in adrenocortical neoplasia. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 111-117.	3.2	31

#	ARTICLE	IF	CITATIONS
145	1 α ,25-Dihydroxyvitamin D ₃ Up-Regulates Bcl-2 Expression and Protects Normal Human Thyrocytes from Programmed Cell Death*. <i>Endocrinology</i> , 1999, 140, 1649-1656.	2.8	30
146	Thyroid Carcinoma Metastasis to Skull with Infringement of Brain: Treatment with Radioiodine. <i>Thyroid</i> , 2009, 19, 297-303.	4.5	30
147	Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. <i>Head and Neck</i> , 2013, 35, 1083-1090.	2.0	30
148	Transforming properties of a Q18 \hat{a} 'E mutation of the microtubule regulator Op18. <i>Cancer Cell</i> , 2002, 2, 217-228.	16.8	29
149	CDX2 Polymorphisms, RNA Expression, and Risk of Colorectal Cancer. <i>Cancer Research</i> , 2005, 65, 5488-5492.	0.9	29
150	Gastrin Induces Nuclear Export and Proteasome Degradation of Menin in Enteric Glial Cells. <i>Gastroenterology</i> , 2017, 153, 1555-1567.e15.	1.3	28
151	Treatment of Micronodular Lung Metastases of Papillary Thyroid Cancer: Are the Tumors too Small for Effective Irradiation from Radioiodine?. <i>Thyroid</i> , 1998, 8, 215-221.	4.5	27
152	Identification of Somatic Mutations in CLCN2 in Aldosterone-Producing Adenomas. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa123.	0.2	27
153	Identification and Management of Intravagal Parathyroid Adenoma. <i>World Journal of Surgery</i> , 2001, 25, 419-423.	1.6	26
154	Paired Box Gene 8-Peroxisome Proliferator-Activated Receptor- $\hat{1}$ ³ Fusion Protein and Loss of Phosphatase and Tensin Homolog Synergistically Cause Thyroid Hyperplasia in Transgenic Mice. <i>Endocrinology</i> , 2009, 150, 5181-5190.	2.8	25
155	Molecular pathology of adrenal cortical tumors: Separating adenomas from carcinomas. <i>Endocrine Pathology</i> , 2006, 17, 355-364.	9.0	23
156	Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non \hat{a} "small cell lung cancer. <i>Journal of Surgical Research</i> , 2014, 187, 6-13.	1.6	23
157	Pioglitazone Therapy of PAX8-PPAR $\hat{1}$ ³ Fusion Protein Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1277-1281.	3.6	22
158	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. <i>Thyroid</i> , 2019, 29, 619-624.	4.5	22
159	Identification of a Specific Vimentin isoform that Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , 2006, 1, 117727190600100.	2.5	21
160	Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation. <i>Cancer</i> , 2008, 114, 300-306.	4.1	21
161	Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3345-3352.	3.6	21
162	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	1.1	21

#	ARTICLE	IF	CITATIONS
163	Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma. <i>Journal of Biological Chemistry</i> , 2020, 295, 8834-8845.	3.4	21
164	Adrenocortical Tumors: An Integrated Clinical, Pathologic, and Molecular Approach at the University of Michigan. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1440-1443.	2.5	20
165	Transcriptional targeting of oncogene addiction in medullary thyroid cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	19
166	Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1264-1273.	3.7	19
167	Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 319-331.	2.8	18
168	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 50-61.	2.0	18
169	Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , 2006, 1, 175-183.	2.5	18
170	Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. <i>Familial Cancer</i> , 2012, 11, 115-121.	1.9	17
171	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	6.3	17
172	Leiomyoma of the Adrenal Gland Presenting as a Non-Functioning Adrenal Incidentaloma: Case Report and Review of the Literature. <i>Endocrine Pathology</i> , 2007, 18, 239-243.	9.0	16
173	Granular-cell tumor of trachea masquerading as hurthle-cell neoplasm on fine-needle aspirate: A case report. , 2000, 22, 379-382.		14
174	Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. <i>Proteomics - Clinical Applications</i> , 2008, 2, 571-584.	1.6	14
175	Location of ectopic adrenocortical hormone-secreting tumors causing Cushing's syndrome in the paranasal sinuses. <i>Head and Neck</i> , 2009, 31, 699-706.	2.0	14
176	An oncocytic adrenal tumour in a patient with Birt-Hogg-ÅubÃ© syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 925-927.	2.4	14
177	Gene Expression Profiling of Endocrine Tumors Using DNA Microarrays: Progress and Promise. <i>Endocrine Pathology</i> , 2003, 14, 107-116.	9.0	13
178	Targeted Mutational Analysis of Cortisol-Producing Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e594-e603.	3.6	13
179	The Age-Dependent Changes of the Human Adrenal Cortical Zones Are Not Congruent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1389-1397.	3.6	11
180	Overexpression of CXC Chemokines by an Adrenocortical Carcinoma: A Novel Clinical Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3968-3974.	3.6	11

#	ARTICLE	IF	CITATIONS
181	Spontaneous vocal cord paresis and return to normocalcemia: An unusual presentation of parathyroid adenoma with concomitant abscess. <i>Surgery</i> , 1997, 121, 704-707.	1.9	10
182	Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. <i>Endocrine-Related Cancer</i> , 2019, 26, 217-225.	3.1	10
183	Genome-Wide Studies in Thyroid Neoplasia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 311-331.	3.2	9
184	Three Endocrine Neoplasms: An Unusual Combination of Pheochromocytoma, Pituitary Adenoma, and Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2012, 22, 430-436.	4.5	9
185	Genetic variants in thyroid cancer distant metastases. <i>Endocrine-Related Cancer</i> , 2016, 23, L33-L36.	3.1	9
186	Targeted RNAseq of Formalin-Fixed Paraffin-Embedded Tissue to Differentiate Among Benign and Malignant Adrenal Cortical Tumors. <i>Hormone and Metabolic Research</i> , 2020, 52, 607-613.	1.5	9
187	Molecular Profiling and Personalized Predictive Pathology. <i>American Journal of Surgical Pathology</i> , 2006, 30, 402-404.	3.7	7
188	Genetics of aldosterone-producing adenomas with pathogenic KCNJ5 variants. <i>Endocrine-Related Cancer</i> , 2019, 26, 463-470.	3.1	7
189	Classification of adrenal cortical tumors: Promise of the "molecular" approach. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 887-892.	4.7	6
190	Pinpointing a hotspot in adrenal Cushing syndrome. <i>Nature Reviews Endocrinology</i> , 2014, 10, 447-448.	9.6	6
191	65 YEARS OF THE DOUBLE HELIX: Classification of endocrine tumors in the age of integrated genomics. <i>Endocrine-Related Cancer</i> , 2018, 25, T171-T187.	3.1	6
192	Ganglioneuroma Manifesting as an Incidental Adrenal Mass in an Adult With Turner's Syndrome. <i>Endocrine Practice</i> , 2005, 11, 382-384.	2.1	4
193	First Description of Parathyroid Disease in Multiple Endocrine Neoplasia 2A Syndrome. <i>Endocrine Pathology</i> , 2008, 19, 289-293.	9.0	4
194	Assessing Biological Aggression in Adrenocortical Neoplasia. <i>Surgical Pathology Clinics</i> , 2014, 7, 533-541.	1.7	4
195	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2473-2482.	3.6	4
196	Funding Anatomic Pathology Research: A Retrospective Analysis of an Intramural Funding Mechanism. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1270-1273.	2.5	3
197	Clinical Impact of Recent Advances in the Biology of Adrenocortical Cancer. , 2003, 13, 470-478.		2
198	Transcriptome analysis of endocrine tumors: Clinical perspectives. <i>Annales D'Endocrinologie</i> , 2008, 69, 130-134.	1.4	2

#	ARTICLE	IF	CITATIONS
199	Morphologic and Molecular Classification of Human Cancer. , 2006, , 10-20.		2
200	Tumors of the Adrenal Glands; Pathology and Genetics. , 2018, , 18-18.		1
201	Molecular Pathogenesis of Thyroid Neoplasia. , 2021, , 181-185.e5.		1
202	Genomic Applications in Thyroid Cancer. , 2019, , 325-334.		1
203	Genetics of Adrenal Tumors. , 2014, , 313-321.		0
204	Genome-Wide Studies in Adrenocortical Neoplasia. , 2009, , 483-491.		0
205	Benign Lung Tumors. , 2010, , 1171-1185.		0
206	Three Endocrine Neoplasms: An Unusual Combination of Pheochromocytoma, Pituitary Adenoma and Papillary Thyroid Carcinoma. Thyroid, 0, , 111227205407003.	4.5	0